{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:08Z","timestamp":1793924828486,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031580","name":"National Vaccine Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031580","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vaccine.2026.129230","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:19:52Z","timestamp":1791861592000},"page":"129230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10\u00a0\u03bcg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA"],"prefix":"10.1016","volume":"94","author":[{"given":"Kriengkrai","family":"Prasert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutthichai","family":"Nakphook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiraphut","family":"Kittiwatanachod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darunee","family":"Ditsungneon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanlaya","family":"Sornwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Naosri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponthip","family":"Wirachwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isariya","family":"Techatanawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piengthong","family":"Narakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchaiya","family":"Surichan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laina D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S.","family":"Polyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Raghunandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakrarat","family":"Pittayawonganon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sopon","family":"Iamsirithaworn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supakit","family":"Sirilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha P.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabda","family":"Praphasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129230_bb0005","series-title":"COVID-19 epidemiological update","author":"World Health Organization","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129230_bb0010","series-title":"Coronavirus (COVID-19) cases","author":"Edouard Mathieu","year":"2020"},{"key":"10.1016\/j.vaccine.2026.129230_bb0015","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/S2214-109X(20)30229-1","article-title":"Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study","volume":"8","author":"Roberton","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.129230_bb0020","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2011.04.120","article-title":"Development of influenza vaccine production capacity by the government pharmaceutical organization of Thailand: addressing the threat of an influenza pandemic","volume":"29","author":"Surichan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129230_bb0025","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/j.vaccine.2011.02.079","article-title":"WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer","volume":"29","author":"Friede","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129230_bb0030","doi-asserted-by":"crossref","DOI":"10.21037\/jphe-23-47","article-title":"Policy and plan for vaccine production and development in Thailand: narrative review","volume":"7","author":"Jumlongnark","year":"2023","journal-title":"J Public Health Emerg"},{"key":"10.1016\/j.vaccine.2026.129230_bb0035","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129230_bb0040","series-title":"WHO COVID-19 dashboard","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129230_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed9120286","article-title":"Impact of COVID-19 vaccination in Thailand: averted deaths and severe infections across age groups","volume":"9","author":"Wilasang","year":"2024","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129230_bb0050","series-title":"COVID-19 vaccination insights report","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129230_bb0055","series-title":"WHO roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity","author":"World Health Organization Strategic Advisory Group of Experts","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129230_bb0060","first-page":"719","article-title":"Meeting of the strategic advisory group of experts on immunization, September 2024: conclusions and recommendations","volume":"49","author":"World Health Organization","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.129230_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101323","article-title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, phase 1 trial","volume":"45","author":"Pitisuttithum","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.129230_bb0070","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.129230_bb0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2110105119","article-title":"SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern","volume":"119","author":"Lu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.129230_bb0080","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/j.vaccine.2022.04.078","article-title":"Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1\/2 trial in Vietnam","volume":"40","author":"Duc Dang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129230_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126542","article-title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: a randomised, comparator-controlled, phase 2 trial","volume":"44","author":"Thiem","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129230_bb0090","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129230_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijid.2023.01.022","article-title":"Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and omicron variants","volume":"129","author":"Niyomnaitham","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129230_bb0100","series-title":"Vaccines guidance document: status of COVID-19 vaccines within WHO EUL\/PQ evaluation process","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129230_bb0105","article-title":"Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand: a test-negative, case-control study","volume":"10","author":"Intawong","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.vaccine.2026.129230_bb0110","series-title":"Non-inferiority clinical trials to establish effectiveness guidance for industry","author":"Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.vaccine.2026.129230_bb0115","series-title":"Immunobridging to evaluate vaccines","author":"Fink","year":"2021"},{"key":"10.1016\/j.vaccine.2026.129230_bb0120","series-title":"Emergency use authorization for vaccines to prevent COVID-19--guidance for industry","author":"Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.vaccine.2026.129230_bb0125","series-title":"Thailand in brief: demographic","author":"Board of Investment","year":"2021"},{"key":"10.1016\/j.vaccine.2026.129230_bb0130","series-title":"Drug product details (Newcode_U: U1DR1A1072640000111C)","author":"Food and Drug Administration (Thailand), Ministry of Public Health","year":"2026"},{"key":"10.1016\/j.vaccine.2026.129230_bb0135","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129230_bb0140","series-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events","author":"Division of AIDS NIoAaID, National Institutes of Health, US Department of Health and Human Services","year":"2017"},{"key":"10.1016\/j.vaccine.2026.129230_bb0145","series-title":"Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). International council for harmonisation of technical requirements for pharmaceuticals for human use.","author":"International Council for Harmonisation Expert Working Group","year":"2016"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129230_bb0150","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"World Health Organization (WHO) Working Group on the Clinical Characterisation and Management of COVID-19 Infection","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129230_bb0155","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2666-5247(23)00324-5","article-title":"Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI centralized laboratory network: a qualification analysis","volume":"5","author":"Manak","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.129230_bb0160","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2026.129230_bb0165","first-page":"e119","article-title":"Antibody efficacy of inactivated vaccine boosters (CoronaVac) against omicron variant from a 15-month follow-up study","volume":"85","author":"Yin","year":"2022","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.129230_bb0170","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129230_bb0175","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129230_bb0180","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2601039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2601039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:54:13Z","timestamp":1793922853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2601039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S0264410X2601039X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129230","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10\u00a0\u03bcg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129230"}}